Source 1primary paper2026MED
Toolkit/amyloid plaque-specific CD4+ CAR-T cells
amyloid plaque-specific CD4+ CAR-T cells
Also known as: amyloid plaque-specific CAR-T cells, CARs targeting fibrillar forms of aggregated amyloid-b2, CD4+ CAR-T cells
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
To achieve this, we engineered CD4+ T cells with chimeric antigen receptors (CARs) targeting fibrillar forms of aggregated amyloid-b2... we established the feasibility of amyloid plaque-specific CAR-T cells as a potential therapeutic avenue for AD.
Usefulness & Problems
No literature-backed usefulness or problem-fit explainer has been materialized for this record yet.
Published Workflows
Objective: Develop a potential universal cellular immunotherapy for Alzheimer's disease by engineering CD4+ T cells with CARs that target fibrillar aggregated amyloid-b2.
Why it works: The abstract states that the workflow exploits beneficial inflammation-regulating properties of CD4+ T cells while avoiding the need for TCR and peptide-MHC antigen discovery by redirecting specificity through a CAR against fibrillar amyloid-b2.
recognition of fibrillar aggregated amyloid-b2recruitment and expansion of endogenous CD4+ T cells in CNS-associated tissuesCD4+ T-cell engineering with chimeric antigen receptorstherapeutic testing in an Alzheimer's disease mouse context
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A composed arrangement of multiple parts that instantiates one or more mechanisms.
Mechanisms
car-mediated antigen recognitioncellular targeting/localization to amyloid plaquesimmune cell recruitmentTechniques
Computational DesignTarget processes
localizationrecombinationValidation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Observations
successMouseapplication demo
Inferred from claim c4 during normalization. CAR-T treatment promotes expansion and recruitment of endogenous CD4+ T cells into the brain parenchyma and leptomeninges. Derived from claim c4.
Source:
successMousetherapeutic use
Inferred from claim c3 during normalization. Optimized amyloid-targeting CD4+ CAR-T cells can alter amyloid deposition in the dura and reduce parenchymal pathology in the brain. Derived from claim c3.
Source:
Supporting Sources
Ranked Claims
Amyloid-targeting CD4+ CAR-T cells were designed to exploit beneficial properties of CD4+ T cells while circumventing the need for TCR and peptide-MHC antigen discovery.
The study engineered CD4+ T cells with CARs targeting fibrillar forms of aggregated amyloid-b2 to create a potential therapeutic approach for Alzheimer's disease.
Amyloid plaque-specific CD4+ CAR-T cells are feasible as a potential therapeutic avenue for Alzheimer's disease.
CAR-T treatment promotes expansion and recruitment of endogenous CD4+ T cells into the brain parenchyma and leptomeninges.
Optimized amyloid-targeting CD4+ CAR-T cells can alter amyloid deposition in the dura and reduce parenchymal pathology in the brain.
Approval Evidence
1 source5 linked approval claimsfirst-pass slug amyloid-plaque-specific-cd4-car-t-cells
To achieve this, we engineered CD4+ T cells with chimeric antigen receptors (CARs) targeting fibrillar forms of aggregated amyloid-b2... we established the feasibility of amyloid plaque-specific CAR-T cells as a potential therapeutic avenue for AD.
Source:
design rationalesupports
Amyloid-targeting CD4+ CAR-T cells were designed to exploit beneficial properties of CD4+ T cells while circumventing the need for TCR and peptide-MHC antigen discovery.
Source:
engineering objectivesupports
The study engineered CD4+ T cells with CARs targeting fibrillar forms of aggregated amyloid-b2 to create a potential therapeutic approach for Alzheimer's disease.
Source:
feasibilitysupports
Amyloid plaque-specific CD4+ CAR-T cells are feasible as a potential therapeutic avenue for Alzheimer's disease.
Source:
immune modulationsupports
CAR-T treatment promotes expansion and recruitment of endogenous CD4+ T cells into the brain parenchyma and leptomeninges.
Source:
therapeutic effectsupports
Optimized amyloid-targeting CD4+ CAR-T cells can alter amyloid deposition in the dura and reduce parenchymal pathology in the brain.
Source:
Comparisons
No literature-backed comparison notes have been materialized for this record yet.
Ranked Citations
- 1.